Montelukast versus salmeterol in patients with asthma and exercise-induced bronchoconstriction

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 3 II, 1999, Pages 547-553

  Villaran, Cesar ^a   O'Neill, Shane J ^b   Helbling, Arthur ^c   Van Noord, Jan A ^d   Lee, Tak H ^e   Chuchalin, Alexander G ^f   Langley, Stephen J ^g   Gunawardena, Kulasiri A ^h   Suskovic, Stanislav ⁱ   Laurenzi, Martino ^j   Jasan, Jay ^j   Menten, Joris ^j   Leff, Jonathan A ^j  

^a CLÍNICA RICARDO PALMA   (Peru)

^b BEAUMONT HOSPITAL   (Ireland)

^c UNIVERSITY OF BERN   (Switzerland)

^d Sittard Geleen Heerlen   (Netherlands)

^e GUY S HOSPITAL   (United Kingdom)

^f Research Institute of Pulmonology   (Russian Federation)

^g WYTHENSHAWE HOSPITAL   (United Kingdom)

^h Chiltern International Ltd   (United Kingdom)

ⁱ Institute of Lung Diseases and Tuberculosis Golnik   (Slovenia)

^j MERCK RESEARCH LABORATORIES   (United States)

more..

Author keywords

Exercise induced asthma; Leukotrienes; Montelukast; Salmeterol; Tachyphylaxis; Tolerance

Indexed keywords

MONTELUKAST; SALMETEROL;

ADOLESCENT; ADULT; AREA UNDER THE CURVE; ARTICLE; ASTHMA; BRONCHOSPASM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EXERCISE INDUCED ASTHMA; FEMALE; FORCED EXPIRATORY VOLUME; HEADACHE; HUMAN; INHALATIONAL DRUG ADMINISTRATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SPIROMETRY;

EID: 0032842408     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(99)70322-2     Document Type: Article

References (34)

1. Anderson SD. Exercise-induced asthma: state of the art. Chest 1985;87:191-5S.
2. Freezer NJ, Croasdell H, Doull IJM, Holgate ST. Effect of regular inhaled beclomethasone on exercise and methacholine airway responses in school children with recurrent wheeze. Eur Respir J 1995;8:1488-93.
3. McFadden ER. Exercise-induced asthma: an assessment of current etiologic concepts. Chest 1987;19:515-75.
4. Eggleston PA. A comparison of the asthmatic response to methacholine and exercise. J Allergy Clin Immunol 1979;63:104-10.
5. Ramage L, Lipworth BJ, Ingram CG, Cree IA, Dhillon DP. Reduced protection against exercise induced broncho con striction after chronic dosing with salmeterol. Respir Med 1994;88:363-8.
6. Yates DH, Kharitonov SA, Barnes PJ. An inhaled glucocorticoid does not prevent tolerance to the broncho protective effect of a long-acting inhaled β2-agonist. Am J Respir Crit Care Med 1996;154:1603-7.
7. Bhagat R, Kalra S, Swystun VA, Cockcroft DW. Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 1995; 108:1235-9.
8. Inman MD, O'Byrne PM. The effect of regular inhaled albuterol on exercise-induced bronchoconstriction. Am J Respir Crit Care Med 1996;153:65-9.
9. 4 after exercise and attenuation of exercise-induced bronchospasm by montelukast, a cysteinyl leukotriene receptor antagonist. Thorax 1997;52:1030-5.
10. 4-receptor antagonist. N Engl J Med 1990;323:1736-9.
11. Bronsky EA, Kemp JP, Zhang J, Guerreiro D, Reiss TF. Dose-related protection of exercise bronchoconstriction by montelukast, a cysteinyl leukotriene-receptor antagonist, at the end of a once-daily dosing interval. Clin Pharmacol Ther 1997;62:556-61.
12. 4 receptor antagonist ICI 204,219 against exercise-induced asthma. Am Rev Respir Dis 1993;147:1413-8.
13. Kemp JP, Dockhorn RJ, Shapiro GG, Nguyen HH, Reiss TF, Seidenberg BC, et al. Montelukast once daily inhibits exercise-induced bronchocon-striction in 6- to 14-year old children with asthma. J Pediatr 1998;133:424-8.
14. Leff JA, Busse WW, Pearlman D, Bronsky EA, Kemp J, Hendeles L, et al. Montelukast, a leukotriene-receptor antagonist, for the treatment of mild asthma and exercise-induced bronchoconstriction. N Engl J Med 1998;339:147-52.
15. Reiss TF, Sorkness CA, Stricker W, Botto A, Busse WW, Kundu S, et al. Effects of montelukast (MK-0476), a potent cysteinyl leukotriene receptor antagonist, on bronchodilation in asthmatic subjects treated with and without inhaled corticesteroids. Thorax 1997;52:45-8.
16. Altman LC, Munk Z, Seltzer J, Noonan N, Shingo S, Zhang J, et al. A placebo-controlled, dose ranging study of montelukast, a cysteinyl leukotriene receptor antagonist. J Allergy Clin Immunol 1998;102:50-6.
17. Reiss TF, Chervinsky P, Dockhorn RJ, Shingo S, Seidenberg B, Edwards TB. Montelukast, a once-daily leukotriene receptor antagonist, in the treatment of chronic asthma: a multicenter, randomized, double-blind trial. Arch Intern Med 1998;158:1213-20.
18. Knorr BA, Matz J, Bernstein JA, Nguyen H, Seidenberg B, Reiss TF, et al. Montelukast for chronic asthma in 6- to 14-year old children. JAMA 1998;279:1181-6.
19. 1 receptor antagonist, improves the signs and symptoms of asthma over one year of treatment. Eur Respir J 1997;10:437S.
20. Knorr BA, Matz J, Sveum RJ, Becker A, Reiss TF, Seidenberg BC, et al. Montelukast (MK-0476) improves asthma over six months of treatment in 6-14-year-old patients. Eur Respir J 1997;10:219S.
21. Diamant Z, Grootendorst DC, Veselic-Charvat M, Timmers MC, De Smet M, Leff JA, et al. The effect of montelukast (MK-0476), a cysteinyl leukotriene receptor antagonist, on allergen-induced airway responses and sputum cell counts in asthma. Clin Exp Allergy 1999;29:42-51.
22. Pizzichini E, Leff JA, Reiss TF, Hendeles L, Boulet LP, Wei LX, et al. Montelukast reduces airway eosinophilic inflammation in asthma: a randomized, controlled trial. Eur Respir Rev. In press.
23. Standardization of spirometry. Am J Respir Grit Care Med 1995;152:1107-36.
24. Global initiative for asthma: global strategy for asthma management and prevention NHLBI/WHO Workshop report. Bethesda (MD): National Institutes of Health, National Heart, Lung, and Blood Institute; 1995. Publication No.:#95-3659.
25. Meltzer SS, Hasday JD, Cohn J, Bleecker ER. Inhibition of exercise-induced bronchospasm by zileuton, a 5-lipoxygenase inhibitor. Am J Respir Crit Care Med 1996;153:931-5.
26. Williams J, Gierczak S, Meltzer S, Nadel A, Jungerwirth S, Bleecker E. Effect of the leukotriene synthesis inhibitor BAY y 1015 on exercise-induced bronchospasm in patients with asthma [abstract]. Am J Respir Crit Care Med 1996;153:A803.
27. 4-receptor antagonist cinalukast. J Allergy Clin Immunol 1997;99:210-5.
28. Simons FER, Gerstner TV, Cheang MS. Tolerance to the broncho protective effect of salmeterol in adolescents with exercise-induced asthma using concurrent inhaled glucocorticoid treatment. Pediatrics 1997;99:655-9.
29. Turpin J, Edelman JM, DeLucca PT, Pearlman DS. Chronic administration of montelukast (MK-476) is superior to inhaled salmeterol in the prevention of exercise-induced bronchoconstriction (EIB) [abstract]. Am J Respir Crit Care Med 1998;157:A456.
30. Drotar DE, Davis EE, Cockcroft DW. Tolerance to the broncho protective effect of salmeterol 12 hours after starting twice daily treatment. Ann Allergy Asthma Immunol 1998;80:31-4.
31. Dente EL, Giannini D, Carletti A, Bacci E, Di Franco A, Macchioni P, et al. Tolerance to the protective effect of salmeterol on early and late asthmatic responses induced by allergen challenge in asthmatics [abstract]. Am J Respir Crit Care Med 1997;155:A344.
32. Yates DH, Sussman HS, Shaw MJ, Barnes PJ, Chung KF. Regular for-moterol treatment in mild asthma: effect on bronchial responsiveness during and after treatment. Am J Respir Crit Care Med 1995;152:1170-4.
33. Grove A, Lipworth BJ. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patienta. Lancet 1995;346:201-6.
34. Booth H, Bish R, Walters J, Whitehead F, Walters EH. Salmeterol tachyphylaxis in steroid treated asthmatic subjects. Thorax 1996;51:1100-4.